High Mobility Group Protein B1 Market Overview
The High Mobility Group Protein B1 Market was valued at USD 632.38 Million in 2025 and is projected to reach USD 1.05 Billion by 2032, growing at a CAGR of 7.5% during 2026–2032, with North America holding the largest share.
Primary Drivers
- Rising research investment in inflammatory and autoimmune disease mechanisms is driving demand for HMGB1 research reagents and assays.
- Growing interest in HMGB1 as a biomarker for sepsis, cancer, and inflammatory conditions is boosting diagnostic research applications.
- Increasing pharmaceutical R&D investment in HMGB1-targeted therapeutics is expanding demand for related research tools.
Primary Challenges
- High costs of specialized research-grade reagents and assay kits limit accessibility for smaller research institutions.
- Limited clinical validation and standardization of HMGB1 biomarker testing can slow broader diagnostic adoption.
- Niche research application scope limits the overall addressable market compared to broader biomarker categories.
This report includes a dedicated chapter covering supply chain exposure, export controls, sanctions risk, and regulatory shifts affecting High Mobility Group Protein B1 Market.
High Mobility Group Protein B1 Market Strategic Outlook
Growth trajectory, 2026–2032
How this market is covered
Revenue split by type
Revenue by end use
High Mobility Group Protein B1 (HMGB1) also known as High mobility group box 1 or SBP-1 is protein encoded by HMGB1 gene. HMGB1 is secreted by immune cells such as monocytes, macrophages, and dendritic cells through leaderless secretory pathway. Activated macrophages and monocytes secrete HMGB1. High Mobility Group Box protein 1 (HMGB1) is a non-alkaline (non-histonic) DNA-binding protein, it is normally localized in the nucleus as part of the chromatin. High Mobility Group Protein B1 is member of chromatin proteins which also includes, HMG1, HMG 2, HMG 14, and HMG 17.
HMGB1 with its high positive charge binds to DNA leads to oxidation, hyperacetylation and posttranslational modifications. HMGB1 is responsible for Stabilization of the nucleosomal structure and regulation of gene transcription in chromatin. It is released by necrotic cells hence act as chaperone to shuttle nuclei acids into the endosomal compartment of APCs. Nucleic acid sensors like TLR9 trigger due to High Mobility Group Protein B1 (HMGB1) . HMGB1 also has the ability to bind LPS, at the level of lipid A, possibly because of its high positive electric charge. It can chaperone to the CD14-TLR4 MD2 complex, increasing the response of macrophages to the LPS.
High Mobility Group Protein B1 (HMGB1) has its importance in:
- Cellular processes such as inflammation, cell differentiation and tumor cell migration.
- Clearance of apoptotic cells, such as in autoimmune diseases
- Splicing results in multiple transcript variants that encode the same protein.
- Antibodies that neutralize HMGB1 can be used to protects against damage and tissue injury during arthritis, lupus erythematosus, colitis, sepsis, endotoxemia, and ischemia.
- thermodynamic stability with electrostatic interactions between the acidic tail and the HMG box.
- The C-terminal acidic tail of HMGB1 helps in the maintenance of protein stability.
High Mobility Group Protein B1 Market : Key Player
- Affibody AB
- Cantex Pharmaceuticals Inc
- Dicerna Pharmaceuticals Inc
- Evec Inc
- Ribomic Inc
High Mobility Group Protein B1 Market: End User / Application Type
- Autoimmune Disorders
- Cerebral Infarction
- Chemotherapy Effects
- Cancer Treatment
High Mobility Group Protein B1 Market : Product Type
- Dociparstat Sodium
- RBM-005
- EV-007156
Global High Mobility Group Protein B1 Market: Regional Analysis
-
North America
- U.S.A
- Canada
- Europe
- France
- Germany
- Spain
- UK
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South East Asia
- Latin America
- Brazil
- Middle East and Africa
High Mobility Group Protein B1 Market Report delivers a comprehensive analysis of the following parameters :
- Market Forecast for
- Market growth drivers
- Challenges and Opportunities
- Emerging and Current market trends
- Market player Capacity, Production, Revenue (Value)
- Supply (Production), Consumption, Export, Import analysis
- End-user/application Analysis
Biotechnology Landscape
Report Coverage
| Parameter | Details |
|---|---|
| Base Year | 2025 |
| Historical Data | 2020 – 2025 |
| Forecast Period | 2026 – 2032 |
| Base Year Value | USD 632.38 Million |
| Forecast Value | USD 1.05 Billion |
| CAGR | 7.5% |
| Regional Scope | North America · Europe · Asia-Pacific · Latin America · MEA · RoW |
Frequently Asked Questions
High Mobility Group Protein B1 Market was valued at USD 632.38 Million in 2025 and is estimated to reach USD 1.05 Billion by 2032.
High Mobility Group Protein B1 Market is projected to grow at a CAGR of 7.5% during 2025–2032.
1. Rising research investment in inflammatory and autoimmune disease mechanisms is driving demand for HMGB1 research reagents and assays. 2. Growing interest in HMGB1 as a biomarker for sepsis, cancer, and inflammatory conditions is boosting diagnostic research applications. 3. Increasing pharmaceutical R&D investment in HMGB1-targeted therapeutics is expanding demand for related research tools.
Yes. The report includes a dedicated section on geopolitical risk factors and their impact on supply chains, pricing, and regional demand dynamics.